Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ebastine versus mebeverine for non-constipated irritable bowel syndrome
2022-501780-41-00Phase 3Completed
- Sponsor
- UZ Leuven
- Start
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in irritable bowel syndrome (IBS) comparing Ebastine arm with Mebeverine arm (2 arms). Primary endpoints: Abdominal Pain Intensity and Global Relief of Symptoms. Started May 2023; status: completed.
02
Drugs
eribulinmebeverine
03
Conditions
irritable bowel syndrome (IBS)
Beyond the preview
Go deeper on 2022-501780-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501780-41-00.